Testosterone Cipionate
Metastatic Prostate Carcinoma
Explore 229 assets in Metastatic Prostate Carcinoma →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07142551CT.gov Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | — | Recruiting | — | — | — |
NCT07476001CT.gov Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC | — | Recruiting | — | — | — |
NCT06922318CT.gov The COSMYC Trial (COmbined Suppression of MYC) | — | Recruiting | — | — | — |
NCT06305598CT.gov Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06100705CT.gov Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC | — | Recruiting | — | — | — |
NCT03554317CT.gov COMbination of Bipolar Androgen Therapy and Nivolumab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Testosterone Cipionate (this asset) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | CCC · 55 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
| Carboplatin | Case Comprehensive Cancer Center | P3 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Testosterone Cipionate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P2 | BB · 64 |
| Hypogonadism, Male | — | P4 | B · 62 |
| Prostate Cancer | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Testosterone Cipionate in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/testosterone-cipionate-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →